Fundz

Nov Ab, Inc. reported raising in an initial SEC Form D filing, from an offering of $600,000

PRIVATESep 30, 2016$0 of $600K raised

Round Type

Venture

TuckerBiotechnology

Quick answer

NovAb raised an undisclosed amount in a funding round, dated September 30, 2016. NovAb is based in Tucker, Georgia, United States.

How much did NovAb raise?
NovAb raised an undisclosed amount in a funding round on September 30, 2016.
What does NovAb do?
NovAb is the developer of monoclonal antibodies (mAbs) designed to utilize variable lymphocyte receptors (VLRs) to develop therapeutic drugs and diagnostic and biomedical research reagents.
Where is NovAb based and how big is it?
NovAb is based in Tucker, Georgia, United States. Fundz records about 3 employees.
Who are the decision-makers at NovAb?
Fundz holds 1 contact at NovAb. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as NovAb that raised within 45 days of this round, from Fundz verified event records.

  • Amyris raised $8.5M on November 14, 2016.
  • Aerpio Therapeutics, Inc. raised $3.5M (Seed) on November 14, 2016.
  • BNB Plus raised $5M on November 14, 2016.
  • Glycomine, Inc. raised $4.9M (Seed) on November 14, 2016.
  • Crispr Therapeutics raised $35M on November 4, 2016.
  • TuHURA Biosciences raised an undisclosed amount on November 4, 2016.

Who to call at NovAb, and when

A new round usually means NovAb is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day NovAb raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at NovAb, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at NovAb. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

NovAb

Location

Tucker, Georgia, United States

About

NovAb is the developer of monoclonal antibodies (mAbs) designed to utilize variable lymphocyte receptors (VLRs) to develop therapeutic drugs and diagnostic and biomedical research reagents. The company develops leucine-rich repeat motifs that form a rigid binding site structure that is contained within a single polypeptide for immune receptors that are not immunoglobulin (Ig) and a new category of research reagents that recognize glycans, thereby enabling researchers and scientists to enhance biomedical research and therapeutic strategies.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment NovAb raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts5 people are listed at NovAb. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for NovAb's next move

See what Strategic adds

NovAb raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.